logo-loader

Open Orphan has 'firmly established its core pharma services offering'

Published: 10:41 02 Jun 2021 BST

Proactive analyst Emma Ulker talks to Proactive London about Open Orphan (LON:ORPH). 

She says ORPH has firmly established its core pharma services offering, underpinned
by the world-leading quarantine facilities, unique challenge study models and its established clinical trial services. 

ORPH is focusing on converting an extensive and substantial amount of non-Covid-19 related services worth over £100mln. This is in addition to substantial contracts already
signed with the UK Government for COVID-19 vaccine challenge studies.

Click here to read Proactive analyst Emma Ulker's latest research note on 'Open Orphan: Unlocking the value of non-core assets'

hVIVO chairman Cathal Friel says he remains committed to hVIVO following...

hVIVO PLC (AIM:HVO) chairman Cathal Friel joined Proactive's Stephen Gunnion to discuss the sale of shares in hVIVO PLC by directors, including himself. Friel explained his decision to sell a portion of his shares in hVIVO was to accommodate the high demand from major institutions while...

on 19/2/24